4d Pharma's (LON:DDDD) Duncan Peyton tells Proactive London's Andrew Scott its phase II clinical trial of oral immunomodulator MRx-4DP0004 for patients in hospital with COVID-19 is now open to enrolment. Dosing of the first patients should begin shortly and Peyton says that as MRx-4DP0004 is a live biotherapeutic it's expected to show a favourable safety profile.
view4D pharma plc
4d Pharma's Duncan Peyton updates as enrolment begins for Phase II COVID-19 study
Quick facts: 4D pharma plc
Price: 160 GBX
LSE:DDDD
Market: LSE
Market Cap: £210.23 m
Follow
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of 4D pharma plc named herein, including the promotion by the Company of 4D pharma plc in any Content on the Site, the Company receives from said...
FOR OUR FULL DISCLAIMER CLICK HEREMost read
Mining
Tesla’s 'battery day' next Tuesday could be ground-breaking for several...
1 day, 11 hours ago
Telecoms & Networks
LOOP Insights inks agreement with TELUS to conduct pilot across three retail...
2 days, 7 hours ago
Health
MMJ Group investees start capitalising on growing demand for cannabis products
5 days, 20 hours ago
